KUALA LUMPUR (Feb 26): Duopharma Biotech Bhd (KL:DPHARMA) saw its net profit for the latest fiscal year rise to a new record high on the back of resilient demand, complemented by a one-off surge in insulin supply in the year’s first half. Net profit for the financial year ended Dec 31, 2025 (FY2025) climbed 39.6% to RM87.46 million — its highest annual net profit on record — from RM62.65 million in FY2024, according to the drugmaker’s bourse filing on Thursday. Resilient demand from both the public and private sectors across all business segments drove a 14.5% growth in revenue to a record RM931.69 million from RM813.67 million previously. Net profit for the last three months ended Dec 31, 2025 (4QFY2025) rose 26.3% to RM19.05 million from RM15.08 million a year earlier, as revenue increased 16% to RM224.69 million from RM193.67 million. “Looking ahead, the new leadership at Duopharma will remain proactively focused on enhancing operational efficiencies, optimising cost management strategies, and executing strategic initiatives,” said Duopharma group CEO Wan Amir-Jeffery Wan Abdul Majid.

Source: The Edge Markets February 26, 2026 12:34 UTC